Home > Cardiology > ACC/WCC 2020 > Interventional Cardiology > TAVR safe and effective in low-risk bicuspid aortic stenosis patients

TAVR safe and effective in low-risk bicuspid aortic stenosis patients

Presented By
Dr B. Ramlawi, Valley Health System, USA
Conference
ACC 2020
Low-risk bicuspid aortic stenosis patients who underwent transcatheter aortic valve replacement (TAVR) with Evolut supra-annular, self-expanding valve achieved promising early results with low early rates of death or disabling stroke, according to Dr Basel Ramlawi (Valley Health System, USA) [1]. The objective of the study was to assess safety and efficacy of TAVR in patients with bicuspid aortic valve stenosis and low surgical risk with a follow-up of 10 years. The primary safety endpoint was all-cause mortality or disabling stroke at 30 days; the primary efficacy endpoint was device success. The study was performed in high-volume experienced centres, which recommended annular sizing and strongly encouraged pre-TAVR balloon dilatation (91.3%). The study included 150 patients with bicuspid aortic valve anatomy confirmed by multi-slice CT. They were either symptomatic or asymptomatic and their predicted risk of mortality was <3%. Mean age of the patient...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on